Peringatan Keamanan

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression.

Ethosuximide

DB00593

small molecule approved

Deskripsi

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.

Struktur Molekul 2D

Berat 141.1677
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 53 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bioavailability following oral administration is 93%.

Metabolisme

Hepatic, via CYP3A4 and CYP2E1.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with food.

Interaksi Obat

1645 Data
Ceritinib Ethosuximide may increase the bradycardic activities of Ceritinib.
Ivabradine Ethosuximide may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Ethosuximide.
Buprenorphine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Hydrocodone Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Ethosuximide can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Ethosuximide may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Mirtazapine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Orphenadrine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Pramipexole Ethosuximide may increase the sedative activities of Pramipexole.
Ropinirole Ethosuximide may increase the sedative activities of Ropinirole.
Rotigotine Ethosuximide may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ethosuximide.
Sodium oxybate Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Thalidomide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amphetamine Amphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phentermine Phentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pseudoephedrine Pseudoephedrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Benzphetamine Benzphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Diethylpropion Diethylpropion can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lisdexamfetamine Lisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mephentermine Mephentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
MMDA MMDA can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Midomafetamine Midomafetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tenamfetamine Tenamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Chlorphentermine Chlorphentermine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dextroamphetamine Dextroamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metamfetamine Metamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iofetamine I-123 Iofetamine I-123 can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ritobegron Ritobegron can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mephedrone Mephedrone can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methoxyphenamine Methoxyphenamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Gepefrine Gepefrine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phendimetrazine Phendimetrazine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mefloquine The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Ethosuximide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Cimetidine The serum concentration of Ethosuximide can be increased when it is combined with Cimetidine.
Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Ethosuximide.
Efavirenz The serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.
Melatonin The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Melatonin.
Nafcillin The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Nafcillin.
Nitroprusside Ethosuximide may increase the hypotensive activities of Nitroprusside.
Valproic acid The serum concentration of Valproic acid can be decreased when it is combined with Ethosuximide.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.
Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Ethosuximide.
Lithium citrate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium citrate.
Lithium carbonate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Lithium hydroxide.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Ethosuximide.
Boceprevir The serum concentration of Ethosuximide can be increased when it is combined with Boceprevir.
Ethanol Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
Ritanserin The risk or severity of adverse effects can be increased when Ethosuximide is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Ethosuximide is combined with Alaproclate.
Sibutramine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sibutramine.
Escitalopram The risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.
Fluvoxamine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluvoxamine.
Citalopram The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.
Paroxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
Zimelidine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Ethosuximide is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Ethosuximide is combined with Indalpine.
Carteolol Ethosuximide may increase the arrhythmogenic activities of Carteolol.
Tocainide Ethosuximide may increase the arrhythmogenic activities of Tocainide.
Metipranolol Ethosuximide may increase the arrhythmogenic activities of Metipranolol.
Aprindine Ethosuximide may increase the arrhythmogenic activities of Aprindine.
Xylometazoline Ethosuximide may increase the arrhythmogenic activities of Xylometazoline.
Sparteine Ethosuximide may increase the arrhythmogenic activities of Sparteine.
Fasudil Ethosuximide may increase the arrhythmogenic activities of Fasudil.
Spiradoline Ethosuximide may increase the arrhythmogenic activities of Spiradoline.
Tiracizine Ethosuximide may increase the arrhythmogenic activities of Tiracizine.
Ethacizine Ethosuximide may increase the arrhythmogenic activities of Ethacizine.
Hydroquinine Ethosuximide may increase the arrhythmogenic activities of Hydroquinine.
Bioallethrin Ethosuximide may increase the arrhythmogenic activities of Bioallethrin.
Fosfructose Ethosuximide may increase the arrhythmogenic activities of Fosfructose.
Hydroquinidine Ethosuximide may increase the arrhythmogenic activities of Hydroquinidine.
SOR-C13 Ethosuximide may increase the arrhythmogenic activities of SOR-C13.
Digoxin Digoxin may increase the arrhythmogenic activities of Ethosuximide.

Target Protein

Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G

Referensi & Sumber

Synthesis reference: Miller, C.A. and Long, L.M.; U.S. Patent 2,993,835; July 25,1961; assigned to Parke, Davis and Company.
Artikel (PubMed)
  • PMID: 16302888
    Patsalos PN: Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia. 2005;46 Suppl 9:140-8.
  • PMID: 2710401
    Coulter DA, Huguenard JR, Prince DA: Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett. 1989 Mar 13;98(1):74-8.
  • PMID: 2545161
    Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93.
  • PMID: 2169941
    Coulter DA, Huguenard JR, Prince DA: Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol. 1990 Aug;100(4):800-6.
  • PMID: 1336826
    Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN: Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience. 1992 Dec;51(4):755-8.

Contoh Produk & Brand

Produk: 25 • International brands: 9
Produk
  • Ethosuximide
    Capsule • 250 1/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Capsule, liquid filled • 250 mg/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Ethosuximide
    Solution • 250 mg/5mL • Oral • US • Generic • Approved
  • Ethosuximide
    Solution • 250 mg/5mL • Oral • US • Generic • Approved
Menampilkan 8 dari 25 produk.
International Brands
  • Emeside — Chemidex
  • Ethymal — Apotex Europe
  • Etoxin — Apsen
  • Petimid — Osel
  • Petinimid — Gerot
  • Petnidan — Desitin
  • Suxilep — Jenapharm
  • Suxinutin — McNeil
  • Zarondan — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul